© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - Building a Better Future
Posted 30th April 2020

Building a Better Future

There are few things in the world that can unite people quite like the universal burden of cancer and neurodegenerative diseases. A company located on the German border near the Czech Republic remains wholly dedicated to the ongoing fight to erase these diseases forever. After its recognition as a Leading Innovator in AI-Based Personalised Medicine Solutions 2020 – Germany, we shine a light on the work of BioVariance GmbH in this latest issue of Acquisition International.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Building a Better Future

BioVariance GmbH

There are few things in the world that can unite people quite like the universal burden of cancer and neurodegenerative diseases. A company located on the German border near the Czech Republic remains wholly dedicated to the ongoing fight to erase these diseases forever. After its recognition as a Leading Innovator in AI-Based Personalised Medicine Solutions 2020 – Germany, we shine a light on the work of BioVariance GmbH in this latest issue of Acquisition International.

When someone becomes sick, physicians usually draw on the common range of medicines and pills. Paracetamol, Ibuprofen and other household drug brands will help most people overcome a headache or other minor aches. However, for the severe cases, such as cancer or neurodegenerative diseases, there is a rapid and strong need to find the right type of medicine that patients will potentially respond to. It is this need that the team of BioVariance have sought to address, by analysing complex biomedical and genetic data from patients to ensure they receive a personalized treatment. Founded in 2013 and headquartered in Waldsassen, Germany, BioVariance’s multidisciplinary team consisting of software developers, biologists and data scientists develops innovative AI solutions for precision medicine in the healthcare, biotech and pharmaceutical sectors.

In cooperation with oncological clinics, laboratories, pharmaceutical companies and physicians all over the country, BioVariance offers long-term monitoring of molecular changes in patients to predict the effectiveness, side effects and drug interactions of specific medications. The company also helps to determine the optimal medication and dosage for each patient individually. Achieving this level of information is not easy at all and requires the combination of profound knowledge with state-of-the-art automatization and parallelization techniques, machine learning and mathematical algorithms to analyse complex biomedical data.

The vision of BioVariance is shared by people all over the world: the eradication of complex diseases and the increase of survival rates by making cancer and neurodegenerative diseases as treatable as the common cold. The company totally focuses on the improvement of patient’s health and quality of life by analysing and interpreting his biomedical data. Working at the junction of some of the most modern technologies, BioVariance represents the fusion of molecular genetics, big data and artificial intelligence that enables personalized care as never before.

For the multidisciplinary team this work is more than just a job. The work culture is characterised by technological advancement, insatiable curiosity and open-mindedness, based on five core values: integrity, responsibility, collaboration, professionalism and innovation. Rather than seeking to maximise profits, BioVariance values patient care above everything else and strives every day to save human lives.

BioVariance offers its services to pharmaceutical companies, physicians and patients themselves. Pharma companies are supported in the analysis of complex molecular biological and biomedical data by using state-of-the-art techniques to identify fundamental correlations across all biological levels, from DNA to metabolites. The application of machine learning, neuronal networks, mathematical algorithms and statistical methods in combination with existing clinical data ensure the high quality of the analytical results.

All results are validated by searching comprehensive medical literature, with the patient’s data being compared with data already existing in the fields of biology, pharmacology and medicine. By understanding, identifying and evaluating biological markers and molecular signatures, pharma companies can be prepared more than ever to develop new effective drugs and personalized treatments.

These personalized applications are then transferred to the other two focus areas of BioVariance: the physician and the patient. For physicians, the company aims to provide more efficient options when a personalized treatment is required. The goal of personalized medicine is to determine the most suitable medication in the optimal dosage for each patient individually. This is rarely easy, however. Doctors and physicians all over the world depend on correct medical diagnoses that consider the personal characteristics and circumstances of a patient’s life, as well as their genetic and molecular biological background. Comprehensive and accurate genetic analyses can ensure that physicians prescribe only the most effective treatment and avoid wrong prescriptions which lead to strong side effects in the worst case. This is where BioVariance comes in.

Analysing individual genetic characteristics and then comparing them with global literature can help physicians and hospitals optimize therapy and adapt it to the specific needs of the patient. Attending physicians and hospitals all over the country and worldwide can access comprehensive reports that contain information about the patient’s diagnosis, current therapies, previous medications and the results of BioVariance’s genetic analysis. Additionally, information about possible side effects and drug interactions that may occur during certain therapies support the selection of an effective treatment.

Considering genetic impacts, physicians and hospitals can avoid non-responsive therapies, eliminate potential side effects, raise survival rates, increase patients’ satisfaction and save valuable time in the treatment process. The genetic fingerprint of an individual helps determine how it may react to a certain treatment or medication. By tailoring therapies, BioVariance helps alleviate patients’ concerns by ensuring their therapy is designed specifically for them.

A challenge of any therapy is the independent intake of medication; another factor the team of BioVariance has carefully dealt with. The company’s mobile app Pillbox reminds patients to take their medication at a specific time and in the correct dosage. Further, the app documents the therapeutic process, symptoms and side effects to inform the attending physician whether an exchange of medication or an adjustment of dosage is necessary. Being a technical marvel, Pillbox also comes with a diary function, an integrated barcode scanner for an easy addition of drugs to the treatment plan and a chat function allowing direct communication between patient and physician.

Cancer and neurodegenerative diseases are undoubtedly some of the greatest medical concerns of our time, but some that the community is actively working towards addressing every single day. For today’s diagnosed patients the wonders of modern medicine and technology represent more than just a chance. It represents hope. Hope for a brighter future, where families are no longer torn apart by death and disease. Hope that, one day, these diseases will be nothing more than a distant memory.

Contact Details:
Company: BioVariance GmbH
Contact: Dr Josef Scheiber
Website: www.biovariance.com

Categories: Innovation, Leadership


You Might Also Like
Read Full PostRead - Eye Icon
Bank Cyber-Attacks Highlight the Need to Simulate ‘War Games’, Says KPMG
Innovation
18/02/2015Bank Cyber-Attacks Highlight the Need to Simulate ‘War Games’, Says KPMG

KPMG's comment on news showing $1bn (£648m) has been stolen in cyber-attacks since 2013.

Read Full PostRead - Eye Icon
How Maternity Care Organizations Can Improve Adverse-Event Response and Family Communication
News
31/08/2026How Maternity Care Organizations Can Improve Adverse-Event Response and Family Communication

A difficult birth does not end when the emergency is over. A mother may be recovering in an operating room while her baby is taken to the neonatal intensive care unit. Her partner may be walking between departments, trying to understand what happened while upd

Read Full PostRead - Eye Icon
The USA’s Most Innovative Business Leaders 2015
Finance
10/12/2015The USA’s Most Innovative Business Leaders 2015

Senior Star Management Company are a family-owned sheltered community management firm specialising in providing professional, tailored care for their residents. Chief Operations Officer and Senior Vice President Anja Rogers talks us through the firm’s high q

Read Full PostRead - Eye Icon
How mining, energy, and construction teams use SRM software to manage community and regulatory risk
Strategy
25/05/2026How mining, energy, and construction teams use SRM software to manage community and regulatory risk

A major mining project can lose roughly $20 million per week in net present value when community conflict delays production. That figure comes from a 2014 study published in the Proceedings of the National Academy of Sciences, which examined cap

Read Full PostRead - Eye Icon
Navigating the Legal Landscape: Unravelling the Intricacies of Company Merging in Poland
News
05/02/2024Navigating the Legal Landscape: Unravelling the Intricacies of Company Merging in Poland

In the ever-evolving landscape of global business, company mergers have become a strategic tool for growth and survival. Poland, with its dynamic business environment, has witnessed numerous successful company mergers that serve as valuable case studies for bu

Read Full PostRead - Eye Icon
What Makes Gamified Learning Critical for Employee Engagement?
Strategy
04/05/2026What Makes Gamified Learning Critical for Employee Engagement?

Most employees dread training. That is not a secret. Slide decks, policy documents, and monotonous quizzes do very little to spark genuine interest. Gamified learning changes the experience by integrating interactive, reward-based elements directly into educat

Read Full PostRead - Eye Icon
Allen & Overy Advise During HIG European Capital Partners’ Acquisition of Centros Unico
M&A
20/08/2015Allen & Overy Advise During HIG European Capital Partners’ Acquisition of Centros Unico

Allen & Overy Advise During HIG European Capital Partners' Acquisition of Centros Unico

Read Full PostRead - Eye Icon
What is ERP Service?
News
28/01/2022What is ERP Service?

Enterprise Resource Planning, or ERP for short, automates and makes all business activities easier with a centralized and integrated software application. The main objective of ERP is to facilitate the flow of information between all company functions inside t

Read Full PostRead - Eye Icon
Gen Z Is Coming: How Luxury Brands Can Survive and Thrive With the Next Generation 
News
20/07/2022Gen Z Is Coming: How Luxury Brands Can Survive and Thrive With the Next Generation 

Younger generations are continuing to encroach on the luxury market, and for brands it is important they get their share. Set to make up 50% of the whole market by 2025, Gen Zs and Millennials are fast becoming key stakeholders in the industry. For luxury bran



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow